Helping the body make its own medicine.
ValamAi designs RNA therapeutics that selectively trigger a patient’s own cells to produce therapeutic proteins — exactly where they are needed most.
Most disease-relevant proteins are out of reach. RNA changes that.
Proteins are large, complex molecules that play a critical role in the body’s capacity to stay healthy. Most approved drugs today are small molecules or protein biologics, which can only reach a limited number of proteins or genes.
RNA therapeutics are a new class of medicines with broad applicability against disease-relevant proteins. ValamAi is building a differentiated pipeline of first-in-class RNA medicines, powered by a proprietary mRNA technology platform, to bring new options to patients with limited treatment alternatives.
How our platform worksThree pillars. One mRNA platform.
Our technology can be applied to a broad number of targets across a range of tissues and diseases — and is amenable to any nucleotide therapy.
Protein Secretion
Engineered mRNA that directs a patient’s cells to produce and secrete their own functional, therapeutic proteins.
Multi-Protein Target
One RNA molecule that up- and down-regulates several therapeutic proteins independently, combining synergistic mechanisms.
Topical Dermatology
RNA in a topical cream format, opening precision dermatology targets that small molecules cannot reach.
First-in-class programs, advancing to the clinic.
Milestones & announcements
ValamAi Announces Grant of First Patent for “Signal Peptide With Heterologous Protein”
Read moreValamAi Highlights Founding Science Behind VMB-100, Published in Molecular Therapy – Nucleic Acids (2023)
Read moreValamAi Welcomes Prof. Friedrich Metzger to its Scientific Advisory Board
Read morePartner with ValamAi
We welcome conversations about co-development, licensing and platform collaborations across urology, orthopedics, dermatology and oncology.